- What is TMS Therapy
- Neurostar Clinical Research
- NeuroStar TMS Therapy System
- NeuroStar Service & Support
After first line treatment attempts with antidepressant medications, patients are often forced to pursue more pharmacotherapy. Few treatment options have been studied and approved by the FDA for use in patients who have not benefited from initial antidepressant treatment. The STAR*D Study also shows that clinical effectiveness declines and intolerance increases with each treatment failure.
As Medication Increases, So Can Side Effects1,3 and the Potential for Treatment Failure1,2,3,4,
In 2010 the American Psychiatric Association (APA) released the 3rd edition of Practice Guidelines for Major Depressive Disorder. In these key treatment guidelines for practicing psychiatrists, transcranial magnetic stimulation (TMS) is cited as an appropriate treatment option for depression patients who have not benefited from initial antidepressant pharmacotherapy.
The following diagram illustrates the 2010 APA Depression Practice Guidelines options for the treatment of depression.
Several other organizations have also acknowledged the scientific evidence for the safety and efficacy of TMS, including:
The clearance of the NeuroStar TMS Therapy® System now provides a new proven depression treatment option for patients who have not benefited from initial antidepressant treatment without systemic side effects.